Oncolys BioPharmaOncolys BioPharma Inc.4588東証グロース医薬品FY ending Dec 2025, non-consolidated, J-GAAP
It lost about ¥7091 for every ¥100 of sales at the operating level. Revenue changed -9.0% from the prior year.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2021 | — | —× | -37.6% | —× | — |
| 2022 | — | —× | -33.1% | —× | — |
| 2023 | — | —× | -82.6% | —× | — |
| 2024 | — | —× | -64.3% | —× | — |
| 2025 | — | —× | -53.1% | —× | — |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 642 | 976 | 63 | 31 | 29 |
| Cost of revenue | 444 | 638 | 32 | 0 | 0 |
| Gross profit | 199 | 338 | 31 | 31 | 29 |
| SG&A | 1,653 | 1,543 | 1,961 | 1,713 | 2,053 |
| Operating income | -1,455 | -1,205 | -1,930 | -1,681 | -2,024 |
| Pretax income | -1,612 | -1,146 | -1,936 | -1,681 | -2,054 |
| Income tax | 4 | 3 | 3 | 4 | 4 |
| Net income attributable to owners | -1,615 | -1,149 | -1,939 | -1,685 | -2,058 |
| Operating margin | -226.4% | -123.4% | -3061.6% | -5357.5% | -7090.5% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥3.21B | ¥1.47B | ¥1.29B | ¥2.17B | ¥3.43B |
| Total assets | ¥4.29B | ¥2.65B | ¥2.04B | ¥3.2B | ¥4.56B |
| Net assets | ¥3.59B | ¥2.16B | ¥1.47B | ¥2.75B | ¥4B |
| Share capital | ¥9.04B | ¥3B | ¥3.62B | ¥5.11B | ¥4.37B |
| Current assets | ¥4.2B | ¥2.61B | ¥1.96B | ¥3.1B | ¥4.49B |
| Current liabilities | ¥430.2M | ¥321.6M | ¥378.5M | ¥252.4M | ¥470.7M |
| Short-term borrowings | ¥238.9M | ¥227.8M | ¥127.8M | ¥127.8M | ¥233.3M |
| Long-term borrowings | ¥255.5M | ¥155.5M | ¥161.1M | ¥166.7M | ¥66.7M |
| Total liabilities | ¥697.9M | ¥491.7M | ¥566.5M | ¥446.6M | ¥555.9M |
| Equity attributable to owners of parent | ¥3.59B | ¥2.15B | ¥1.46B | ¥2.74B | ¥3.99B |
| Retained earnings | -¥14.5B | -¥1.43B | -¥3.37B | -¥5.06B | -¥2.06B |
| Treasury stock | -¥113K | -¥142K | -¥142K | -¥142K | -¥17K |
EDINET (FSA Japan)
有価証券報告書－第22期(2025/01/01－2025/12/31)
EDINET (FSA Japan)
有価証券報告書－第21期(2024/01/01－2024/12/31)
EDINET (FSA Japan)
有価証券報告書－第20期(2023/01/01－2023/12/31)
EDINET (FSA Japan)
有価証券報告書－第19期(2022/01/01－2022/12/31)
EDINET (FSA Japan)
訂正有価証券報告書－第18期(令和3年1月1日－令和3年12月31日)
EDINET (FSA Japan)
有価証券報告書－第17期(令和2年1月1日－令和2年12月31日)
Extracted from XBRL: 40 / Derived from other figures: 2
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.